Simplex Trading’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.56M Buy
42,300
+7,200
+21% +$523K ﹤0.01% 1359
2025
Q4
$2.65M Buy
35,100
+32,300
+1,154% +$2.03M ﹤0.01% 1754
2025
Q3
$111K Buy
2,800
+1,400
+100% +$53.5K ﹤0.01% 5614
2025
Q2
$60K Buy
1,400
+1,300
+1,300% +$49.5K ﹤0.01% 5738
2025
Q1
$3K Hold
100
﹤0.01% 7771
2024
Q4
$4K Sell
100
-100
-50% -$5.1K ﹤0.01% 7699
2024
Q3
$11K Sell
200
-200
-50% -$9.58K ﹤0.01% 7104
2024
Q2
$15K Buy
+400
New +$19.4K ﹤0.01% 7106

Other funds holding APGE

Simplex Trading's APGE Position: Q1 2026 in Review

Simplex Trading increased its Apogee Therapeutics (APGE) stake by 24% in Q1 2026, buying an estimated $1.09M and bringing the position to 77,808 shares worth $6.55M. The position accounts for ﹤0.01% of the portfolio, ranked #925.

Simplex Trading first reported a position in APGE in Q3 2024 and has held it in 4 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Simplex Trading held 77,808 shares of Apogee Therapeutics worth $6.55M as of Q1 2026.
  • Simplex Trading bought 15,009 Apogee Therapeutics shares in Q1 2026, an estimated $1.09M.
  • Apogee Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #925 holding.
  • Simplex Trading first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.